STOCK TITAN
  1. Home
  2. SEC Filings
  3. NTRA
  4. [Form 4] Natera, Inc. Insider Trading Activity

Natera chair sells 100K shares under 10b5-1 plan

Natera, Inc. executive chairman Matthew Rabinowitz reported open-market sales of a total of 100,000 shares of common stock.

Filing Impact
(Very High)
Filing Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Form Type
4

Rhea-AI Filing Summary

Natera, Inc. executive chairman Matthew Rabinowitz reported open-market sales of a total of 100,000 shares of common stock. The transactions took place on June 12 and June 15, 2026 at weighted average prices within ranges from $208.88 to $219.98 per share, according to accompanying footnotes.

The filing states that these sales were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026. Following the transactions, Rabinowitz directly holds 2,277,843 common shares, with an additional 5,000 shares held indirectly by his spouse, indicating he retains a substantial equity position in the company.

Insider Rabinowitz Matthew
Role EXECUTIVE CHAIRMAN
Sold 100,000 shs ($21.45M)
Type Security Shares Price Value
Sale Common Stock 831 $209.8343 $174K
Sale Common Stock 1,832 $210.73 $386K
Sale Common Stock 1,237 $211.8092 $262K
Sale Common Stock 5,097 $212.8363 $1.08M
Sale Common Stock 7,836 $213.8846 $1.68M
Sale Common Stock 10,338 $214.7173 $2.22M
Sale Common Stock 11,877 $215.9079 $2.56M
Sale Common Stock 6,741 $216.8135 $1.46M
Sale Common Stock 3,811 $217.6027 $829K
Sale Common Stock 400 $218.7225 $87K
Sale Common Stock 2,536 $209.4953 $531K
Sale Common Stock 3,267 $210.2993 $687K
Sale Common Stock 2,957 $211.6121 $626K
Sale Common Stock 12,142 $212.2716 $2.58M
Sale Common Stock 5,034 $213.4284 $1.07M
Sale Common Stock 5,707 $214.351 $1.22M
Sale Common Stock 3,161 $215.3797 $681K
Sale Common Stock 7,182 $216.5078 $1.55M
Sale Common Stock 4,276 $217.3242 $929K
Sale Common Stock 2,133 $218.17 $465K
Sale Common Stock 1,605 $219.3581 $352K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 2,277,843 shares (Direct); Common Stock — 5,000 shares (Indirect, By spouse)
Footnotes (22)
  1. F1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
  2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.88 to $209.87 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.88 to $210.87 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.92 to $211.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.92 to $212.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.92 to $213.90 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.92 to $214.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.92 to $215.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. F9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.92 to $216.89 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. F10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.95 to $217.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  11. F11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.96 to $218.64 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  12. F12. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.26 to $219.98 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  13. F13. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.27 to $210.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  14. F14. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.2850 to $211.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  15. F15. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.30 to $212.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  16. F16. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.32 to $213.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  17. F17. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.32 to $214.30 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  18. F18. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.32 to $215.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  19. F19. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.32 to $216.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  20. F20. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.32 to $217.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  21. F21. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.32 to $218.27 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  22. F22. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.61 to $218.84 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 100,000 shares Total open-market sales reported in Form 4
Price range $208.88–$219.98 per share Weighted average price ranges from footnotes
Direct holdings after 2,277,843 shares Direct common stock owned following reported sales
Indirect holdings 5,000 shares Common stock held indirectly by spouse
Rule 10b5-1 plan adoption date March 13, 2026 Plan governing reported sales
Rule 10b5-1 trading plan regulatory
"The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"ownership_type: "indirect" and nature_of_ownership: "By spouse""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Natera (NTRA) shares did Matthew Rabinowitz sell in this Form 4?
Matthew Rabinowitz reported selling a total of 100,000 shares of Natera common stock. These were executed as multiple open-market sales over two trading days, as summarized in the Form 4 transaction data and supporting footnotes.

At what prices were the Natera (NTRA) shares sold by the executive chairman?
The reported sales were executed at weighted average prices within ranges from about $208.88 to $219.98 per share. Footnotes explain that each reported price aggregates numerous individual trades across these specified price intervals.

Was the Natera (NTRA) insider sale made under a Rule 10b5-1 plan?
Yes. A footnote states the share sales were effected under a Rule 10b5-1 trading plan adopted by Matthew Rabinowitz on March 13, 2026. Such plans pre-schedule trades, reducing the significance of short-term market timing.

How many Natera (NTRA) shares does Matthew Rabinowitz hold after these transactions?
After the reported sales, Matthew Rabinowitz directly holds 2,277,843 shares of Natera common stock. The filing also shows an additional 5,000 shares held indirectly through his spouse, reflecting continued substantial ownership.

What is the nature of the Natera (NTRA) indirect holdings reported in this Form 4?
The Form 4 lists an indirect holding of 5,000 Natera shares classified as held "By spouse." This indicates those shares are owned through his spouse rather than in Rabinowitz’s direct name, but are still reported for beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Accepted by SEC EDGAR
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Rabinowitz Matthew
(Last)(First)(Middle)
C/O NATERA, INC.
13011 MCCALLEN PASS BUILDING A SUITE 100
(Street)
AUSTIN TEXAS 78753
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
EXECUTIVE CHAIRMAN
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/12/2026S2,536(1)D$209.4953(2)2,375,307D
Common Stock06/12/2026S3,267(1)D$210.2993(3)2,372,040D
Common Stock06/12/2026S2,957(1)D$211.6121(4)2,369,083D
Common Stock06/12/2026S12,142(1)D$212.2716(5)2,356,941D
Common Stock06/12/2026S5,034(1)D$213.4284(6)2,351,907D
Common Stock06/12/2026S5,707(1)D$214.351(7)2,346,200D
Common Stock06/12/2026S3,161(1)D$215.3797(8)2,343,039D
Common Stock06/12/2026S7,182(1)D$216.5078(9)2,335,857D
Common Stock06/12/2026S4,276(1)D$217.3242(10)2,331,581D
Common Stock06/12/2026S2,133(1)D$218.17(11)2,329,448D
Common Stock06/12/2026S1,605(1)D$219.3581(12)2,327,843D
Common Stock06/15/2026S831(1)D$209.8343(13)2,327,012D
Common Stock06/15/2026S1,832(1)D$210.73(14)2,325,180D
Common Stock06/15/2026S1,237(1)D$211.8092(15)2,323,943D
Common Stock06/15/2026S5,097(1)D$212.8363(16)2,318,846D
Common Stock06/15/2026S7,836(1)D$213.8846(17)2,311,010D
Common Stock06/15/2026S10,338(1)D$214.7173(18)2,300,672D
Common Stock06/15/2026S11,877(1)D$215.9079(19)2,288,795D
Common Stock06/15/2026S6,741(1)D$216.8135(20)2,282,054D
Common Stock06/15/2026S3,811(1)D$217.6027(21)2,278,243D
Common Stock06/15/2026S400(1)D$218.7225(22)2,277,843D
Common Stock5,000IBy spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.88 to $209.87 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.88 to $210.87 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.92 to $211.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.92 to $212.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.92 to $213.90 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.92 to $214.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.92 to $215.91 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.92 to $216.89 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
10. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.95 to $217.92 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
11. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.96 to $218.64 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
12. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.26 to $219.98 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
13. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.27 to $210.22 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
14. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.2850 to $211.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
15. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.30 to $212.28 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
16. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.32 to $213.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
17. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.32 to $214.30 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
18. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.32 to $215.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
19. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.32 to $216.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
20. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.32 to $217.31 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
21. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.32 to $218.27 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
22. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.61 to $218.84 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Tami Chen, Attorney-in-Fact06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on NTRA

All NTRA news

Trending in the feed

LQDA
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH Open the live feed